



## Dicerna to Participate in Jefferies Virtual Global Healthcare Conference

May 26, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--May 26, 2020-- [Dicerna Pharmaceuticals, Inc.](#) (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview as part of the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 4:30 p.m. ET.

A live audio webcast of the presentation will be accessible within the Investors & Media section on the Dicerna website at [www.investors.dicerna.com](http://www.investors.dicerna.com). An archived replay of the webcast will be available on the Company's website after the conference.

### About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. Using our proprietary RNAi technology platform called GalXC™, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By reducing the level of disease-causing genes of the liver, Dicerna's GalXC has the potential to safely target conditions that are difficult to treat with other modalities. Continually innovating, Dicerna is also exploring new applications of RNAi technology beyond the liver, targeting additional tissues and enabling new therapeutic applications. In addition to our own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiovascular, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegeneration and pain. At Dicerna, our mission is to interfere – to silence genes, to fight disease, to restore health. For more information, please visit [www.dicerna.com](http://www.dicerna.com).

### Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements relating to the Company's research and development. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those risks identified under the heading "Risk Factors" included in our most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

GalXC™ is a trademark of Dicerna Pharmaceuticals, Inc.

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20200526005017/en/>

#### Media:

Amy Trevvett, Dicerna Pharmaceuticals, Inc.  
+1 617-612-6253  
[atrevvett@dicerna.com](mailto:atrevvett@dicerna.com)

#### Investors:

Janhavi Mohite, Stern Investor Relations, Inc.  
+1 212-362-1200  
[janhavi.mohite@sternir.com](mailto:janhavi.mohite@sternir.com)

Source: Dicerna Pharmaceuticals, Inc.